Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2006-01-03
2006-01-03
Saoud, Christine J. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S303000, C530S350000, C536S023400, C514S003100, C514S866000
Reexamination Certificate
active
06982323
ABSTRACT:
Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.
REFERENCES:
patent: 5821334 (1998-10-01), Powers
Ramiya et al. J. Autoimmunity. 10: 287-292, 1997.
Falorni et al. Diabetologia. 39: 1091-1098, 1996.
Ammerer, 1983. Meth Enzymol 101:192.
Atkinson and Maclaren, 1993 J Clin Invest 92:1608-1616.
Atkinson et al. 1990 Lancet 335:1357-1360.
Atkinson et al. 1990 Diabetes 39:933-937.
Atkinson et al. 1992 Lancet 339: 458-459.
Atkinson et al. 1993 J Clin Invest 91:350-356.
Baekkeskov et al. 1982 Nature 298:167-169.
Bekkeskov et al. 1987 J Clin Invest 79:926-934.
Baekkeskov et al. 1990 Nature 347:151-156.
Bock et al. 1992 Lancet 339:1504-1506.
Bonifacio et al. 1990 Lancet 335:147-149.
Bowman et al. 1994 Immunol Today 15 (3) :115-120.
Brunner et al. 1995 Nature 373:441-444.
Butler et al. 1993 J Exp Med 178:2097-2106.
Cohen et al. 1992 Ann Rev Immunol 10:267 et seq.
Conrad et al. 1994 Nature 371:351-355.
Cotter et al. 1990 Anticancer Research 10:1153 et seq.
Crispe 1994 Immunity 1:347-349.
Daniel et al. Proc Natl. Acad. Sci. USA 93:956-960.
De Aizpurua et al. 1992 Proc Natl Acad Scie USA 89:9841-9845.
Dhein et al. 1995 Nature 373:438-441.
Evans and Scarpulla 1989 Gene 84:135 et seq.
Garnier et al., 1978 J Mol Biol 120:97-120.
Goeddel et al., 1980 Nucl Acids Res 8:4057 et seq.
Griffin and Griffin, Eds., 1994 PCR Technology, Current Innovations. CRC Press, Boca Raton, FL.
Grosjean and Fiers, 1982 Gene 18:199 et seq.
Hanninen et al., 1992 J Clin Invest 90:1901-1910.
Harrison, 1992 Immunol Today 13:348-352.
Hatfield et al. 1997 Diabetologia 40:1327-1333.
Hernan et al., 1992 Biochemistry 31:8619 et seq.
Herold et al., 1992 J Exp Med 176:1107-1114.
Ho et al. 1989 Gene 77:51-59.
Huang and Gorman, 1990 Mol Cell Biol 10:1805 et seq.
Ju et al. 1995 Nature 373:444-448.
Karjalainen et al., 1992 New Eng J Med 327:302-307.
Kaufman et al., 1993 Nature 366:69-72.
Kawabe and Ochi, 1991 Nature 349:245-248.
Kawaskai et al., 1997 J. Clin. Endocrinol. Metab 82:375-380.
Lenardo, 1991 Nature 353:858-860.
Lohman et al., 1996 J of Autoimmunity 9:385-389.
Lohman et al., 1996 Hormone & Metabolic Res. 28:357-360.
Luckow et al., 1988 Bio/Technology 6:47 et seq.
MacLaren, N and K Laffety 1993 Diabetes 42:1099-1104.
Marrack and Kappler, 1987 Science 238:1073 et seq.
Moir, et al. 1991 Meth Enzymol 194:491-507.
Morgenstern and Land 1990 Nucl Acids Res 18:3587 et seq.
Muir et al., 1995 J Clin Invest 95, pp628-634.
Nagata and Suba, 1995 Immunol Today 16:39 et seq.
Naquet et al., 1988 J Immunol 140:2569-2578.
Quinn, A and E.E. Sercarz 1996 J Autoimmunity 9:365-370.
Ramiya et al., 1996 J. Autoimmunity 9:349-356.
Richter et al., 1992 Proc Natl Acad Sci USA 89:8467-8471.
Russell et al., 1993 Proc Natl Acad Sci USA 90:4409-4413.
Sato et al., 1994 J Biol Chem 269:17267 et seq.
Schena et al., 1991 Meth Enzymol 194:389-398.
Singer et al., 1994 Immunity 1:365-371.
Solimena and De Camilli, 1993 Nature 366: 15-17.
Steinman, 1995 Cell 80:7-10.
Strasser, 1995 Nature 373:385-386.
Sun et al., Eur J Immunol 21:1461-1468.
Taguchi et al., 1990 J Immunol Meth 128:65-73.
Talib et al., 1991 Gene 98:289-293.
Tisch et al., 1993 Nature 366:72-75.
Von Boehmer, 1988 Ann Rev Immunol 6:309 et seq.
Waslston et al., 1995 N Eng J Med 333:343-347.
Wicker et al., 1996 J Clin Invest 98:2597-2603.
Xie et al., 1997 J Immunol 159:3662-3667.
Zhang et al., 1997 Diabetes 46:40-43.
Zhang et al., 1991 Proc Natl Acad Sci USA 88:10252-10256.
Adorini, L et al. 1993Immunol Today14:285-289 Selective Immunosuppression.
Allegretta, M et al/1990Science247:718-722 T Cells Responsive to Myelin basic Protein in Patients with Multiple Sclerosis.
Allegretta, M et al. 1994J Clin Invest94:105-109 Homologies Between T Cell Receptor Junctional Sequences Unique To Multiple Sclerosis And T Cells Mediating Experimental Allergic Encephalomyelitis.
Alvord, EC et al. 1979Ann Neurol6:461-468 Has Myelin Basic Protein Received a Fair Trial in the Treatment of Multiple Sclerosis?
Alvord, EC et al. 1979Ann Neurol6:469-473 Myelin Basic Protein Treatment Of Experimental Allergic Encephalomyelitis in Monkeys.
Amor S, et al. 1994Journal of Immunology153:4349-4356 Identification of Epitopes of Myelin Oligodendrocyte Glycoprotein for the Induction of Experimental Allergic Encephalomyelitis in SJL and Biozzi AB/H Mice.
Aruga, J et al. 1991J Neurochem56:1222-1226 Identification of the New Isoforms of Mouse Myelin Basic Protein: The Existence Of Exon 5a.
Boehme, S et al. 1993.Eur J Immunol23:1552-1560 Propriocidal Apoptosis of Mature T Lymphocytes Occurs at S Phase of the Cell Cycle.
Carnegie P, et al. 1971Biochem J.123:57-67 Amino Acid Sequence of the Encephalitogenic Basic Protein.
Chen, Y et al. 1994Science265:1237-1240 Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis.
Chou, YK et al. 1991J Neurosci Res28:280-290 Specificity of Human T Cell Clones Reactive to Immunodominant Epitopes of Myelin Basic Protein.
Correale, J et al. 1995J Immunology154:2959-2968 Patterns of Cytokine Secretion by Autoreactive Proteolipid Protein-Specific T Cell Clones During the Course of Multiple Sclerosis.
Critchfield, JM et al. 1994Science263:1139-1143 T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis.
Diehl H, et al. 1986Proc. Natl. Acad. Sci. USA83:9807-9811 Individual exons encode the integral membrane domains of human myelin proteolipid protein.
Duvall, et al. 1986Immunol Today7:115-119.
Endoh, M et al. 1986J Immunol137:3832-3835 DM-20, A Proteolipid Apoprotein, Is An Encephalitogen Of Acute And Relapsing Autoimmune Encephalomyelitis In Mice.
Greer, JM et al. 1992J Immunol149:783-788 Identification and Characterization of a Second Encephalitogenic Determinant of Myelin Proteolipid Protein (Residues 178-191) for SJL Mice.
Grima, B et al. 1992J Neurochem59:2318-2323 A Novel Transcript Overlapping the Myelin Basic Protein Gene.
Higgins, Paul J. et al. 1988J Immunol140:440-445. Suppression Of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and its Fragments.
Horvath, L et al. 1990Biochemistry29:2635-2638 Influence of Polar residue Deletions of Lipid-Protein Interactions with the Myelin Proteolipid Protein. Spin-Label ESR Studies with DM-20/Lipid Recombinants.
Johnson, D et al. 1986J Neuroimmunol13:99-108 Cell-Mediated Immunity to Myelin-Associated Glycoprotein, Proteolipid Protein, and Myelin Basci Protein in Multiple Sclerosis.
Kamholz, J et al. 1986Proc Natl Acad Sci USA83:4962-4966 Identification of three forms of human myelin basic protein by cDNA cloning.
Kamholz, J et al. 1988J Neurosci Res21:62-70 Organization and Expression of the Human Myelin Basic Protein Gene.
Kennedy, M et al. 1990J Immunol144:909-915 Inhibition of Murine Relapsing Experimental Autoimmune Encephalomyelitis by Immune Tolerance to Proteolipid Protein and its Encephalitogenic Peptides.
Kerlero De Rosbo, et al. 1993J Clin Invest92:2602-2608 Reactivity to Myelin Antigens in Multiple Sclerosis.
Kronquist, et al. 1987J Neurosci Res18:395-401 Expression of Myelin Proteins in the Developing Human Spinal Cord: Cloning and Sequencing of Human Proteolipid Protein cDNA.
Lehmann, PV et al. 1992Nature358:155-157 Spreading Of T-Cell Autoimmunity To Cryptic Determinants Of An Autoantigen.
Liblau, R et al. 1991Eu
Matis Louis A.
Mueller John
Wang Yi
Alexion Pharmaceuticals, Inc.
Saoud Christine J.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Chimeric proteins for diagnosis and treatment of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric proteins for diagnosis and treatment of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric proteins for diagnosis and treatment of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3596577